February 17, 2022
InSysBio announces its participation in Tau2022 Global Conference. Tau2022 is held virtually on February 22-23, 2022. InSysBio team presents a poster within its frames, namely:
Tatiana comments on the poster, "In the poster we try to anticipate brain dynamics of pathological tau deposits during gosuranemab treatment and predict how early therapy should be started for highest efficacy".
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | May 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
1.
15 May 2025 15:07
15th InSysBio’s Annual Internal Scientific Meeting
InSysBio held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.
|
16
|
17
|
18
|
|
19
|
20
|
21
1.
21 May 2025 16:55
InSysBio to take part in PAGE 2025
InSysBio announces its participation in the Thirty-third PAGE Meeting which is to be held from 4-6 June, 2025, at the Thessaloniki Concert Hall in Thessaloniki, Greece. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #10 in the upper foyer and 2 posters in frames of the Meeting
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
1.
30 May 2025 15:23
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
The new article “Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data” has been recently published in CPT: Clinical Pharmacology & Therapeutics
|
31
| |
Thank you for your message! We will get back to you shortly.
